Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of atezolizumab combined with obinutuzumab or rituximab in relapsed/refractory mantle cell lymphoma, marginal zone lymphoma, and Waldenström macroglobulinemia
2016-003579-22Phase 2Completed
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, obinutuzumab and rituximab in mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZL) and Waldenström macroglobulinemia (WM) (3 cohorts), sponsored by Roche. Primary endpoint: Objective response at end of induction. Started May 2017; status: completed.
02
Drugs
atezolizumabobinutuzumabrituximab
03
Conditions
mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2016-003579-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003579-22.